Can-Fite BioPharma Ltd. CANF
As ofNov 20, 2026, 3:59 PM EST
- YTD
- -64.13%
- 1 year
- -76.85%
5D -0.06 (-4.03%)
- Market cap
- 4.35M
- Revenue (ttm)
- 667.00K
- EPS (ttm)
- -13.23
- Shares out
- 6.10M
- Forward P/E
- -2.00
- YTD return
- -64.13%
- 1-year return
- -76.85%
- 50-day average
- 2.08
- 200-day average
- 2.37
- Volume
- 16.83K
- Avg volume
- 375.13K
- Open
- 1.48
- Previous close
- 1.47
- Day's range
- 1.43 – 1.53
- 52-week range
- 1.42 – 7.80
- Beta
- 0.57
- Analysts
- Strong Buy
- Price target
- 14.00 (+875.6%)
Key statistics
- Enterprise value
- 2.47B
- Price / sales
- 13.34
- Price / book
- 1460.00
- Revenue growth
- -19.40%
- Free cash flow
- -4.55M
- Total cash
- 4.73M
- Total debt
- 57.00K
- Return on equity
- -157.62%
- Short % of float
- 2.51%
Fundamental scorecard
6 of 25 checks passed on CANF’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | EF Hutton | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- canfite.com
News
Can-Fite Biopharma Completes Treatment Of First 247 Patients In Its Phase III Study Evaluating Piclidenoson For Moderate-To-Severe Plaque Psoriasis; Expects Results Of Pre-Specified Interim Analysis In Q1 2027
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session Can-Fite Announces Publication Of Research Showing That Piclidenoson Corrects Disease-Associated Cellular Abnormalities And Improves Kidney Protein Reabsorption In Preclinical Models Of Lowe Syndrome
12 Health Care Stocks Moving In Wednesday's After-Market Session Can-Fite Announces 10-Yr Cancer-Free Survival In Advanced Liver Cancer Patient Treated With Namodenoson
Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on CANF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 42.17% | 650,000 | 949.00K | Sep 29, 2024 |
| Morgan Stanley | 3.29% | 50,660 | 73.96K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 1.92% | 29,570 | 43.17K | Sep 29, 2024 |
| Rhumbline Advisers | 1.10% | 16,945 | 24.74K | Sep 29, 2024 |
| Fifth Third Bancorp | 0.19% | 3,000 | 4.38K | Sep 29, 2024 |
| Wells Fargo & Company | 0.16% | 2,500 | 3.65K | Sep 29, 2024 |
